Fc gamma receptor I, Fc gamma receptor II, and Fc gamma receptor III (FcγRI, FcγRII, FcγRIII)

Fc gamma receptors (FcγRI, FcγRII, FcγRIII) are cell-surface proteins expressed mainly on leukocytes that bind IgG antibodies via their Fc region, mediating a bridge between antibody-mediated recognition and immune effector functions like phagocytosis, cytotoxicity, antigen presentation, and cytokine production[2][5][6]. They are classified by affinity, structure, and signaling: FcγRI is a high-affinity receptor that can bind monomeric IgG, while FcγRII and FcγRIII bind immune complexes with lower affinity[2][6]. Signaling downstream of these receptors relies on immunoreceptor tyrosine-based motifs, with activating (ITAM) and inhibitory (ITIM) variants enabling tight regulatory control[2][5][6]. Variants and polymorphisms impact patient responses to antibody therapeutics; FcγRs are essential for the efficacy of many antibody drugs, especially those relying on ADCC[4]. Therapeutic modulation of FcγR interaction is central to monoclonal antibody drug development, with glycoengineering and Fc-engineering strategies aiming to enhance efficacy and reduce unwanted immune activation[4][6]. The family’s complexity—including multiple subtypes and isoforms—requires detailed classification in drug development and translational medicine[4][5][6].

Other names

CD64 (Fc gamma receptor I)CD32 (Fc gamma receptor II; includes Fc gamma receptor IIa, IIb, IIc)CD16 (Fc gamma receptor III; includes Fc gamma receptor IIIa, IIIb)FcγR (generic for the family)

Antibody-dependent cellular cytotoxicity (ADCC): engagement of FcγRIIIa on NK cells activates killing of antibody-coated targets\nPhagocytosis: activating FcγRs trigger ingestion and destruction of opsonized pathogens\nModulation of immune signaling: ITAM-driven activation or ITIM-driven inhibition of downstream pathways (e.g., tyrosine kinases, PI3K, Syk)\nCytokine release, antigen uptake and presentation